Despite the small sample size, a spectrum of increased α-synuclein levels was observed from GBA1-PD, to sPD, HC, and GBA1-NMC, suggesting that either this increase represents a compensatory mechanism that GBA1-NMC exert, or an early, pathological marker that can decompensate later. This evidence concerns the gene GBA1 and Parkinson disease.